Health technology assessments initiated in the third quarter of 2025 in Poland

The Agency for Health Technology Assessment and Tariff System (AOTMiT) is a consultative and advisory entity supervised by the Minister of Health (MoH) in Poland. The role of the Agency is to assist the MoH in the decision-making process regarding the financing of medicines and medical technologies in the healthcare system.

In the third quarter of 2025, the AOTMiT initiated six Med Tech-related HTAs in diagnostic imaging, endocrine, in-vitro diagnostics, nephrology and urology, and robotic surgery fields.

The examples of the initiated assessments are provided below.

On July 2, 2025, the Agency initiated the preparation of recommendations concerning the qualification of the early detection program for lung cancer in individuals with an increased, defined risk of disease, using low-dose computed tomography (LDCT) as a guaranteed healthcare service:

• On July 25, 2025, the AOTMiT report concluded that LDCT lung cancer screening is clinically justified and likely cost-effective (especially long-term) with expanded eligibility (e.g., 50-80 years, ≥20 pack-years). It should be implemented nationally as a guaranteed service with formal pricing, clear patient pathways and quality indicators, primary healthcare-based pre-qualification, integration of smoking-cessation/chronic obstructive pulmonary disease (COPD) components, and AI radiology support (via the Centre for e-Health platform), while recognizing a substantial budget impact dependent on program uptake;
• Additionally, the position of the Transparency Council justified classifying the program for the early detection of lung cancer in individuals with increased, defined risk using LDCT as a guaranteed service;
• Finally, on August 18, 2025, the recommendations of the President of the AOTMiT were published. The President recommended qualifying the program for the early detection of lung cancer in individuals with an increased, defined risk of developing the disease using LDCT as a guaranteed service.

On August 14, 2025, the AOTMiT began preparing recommendations on the qualification of surgical treatment of malignant kidney tumors using a robotic system as a guaranteed benefit:

• On September 15, 2025, the report of the AOTMiT was published. The AOTMiT concluded that robot-assisted partial/radical nephrectomy is a guideline-accepted, evidence-based alternative to open/laparoscopic surgery that expands nephron-sparing options and offers perioperative benefits but is not separately reimbursed in Poland. Introducing it as a guaranteed service would require clear qualification/implementation criteria, full tariff valuation, and an outcomes registry. It would increase public costs over time, partly offset by shorter stays and fewer complications.

On September 3, 2025, the Agency initiated the preparation of the recommendations to justify qualifying the determination of mitotane concentration in blood serum as a guaranteed service in the scope of outpatient specialist care. No further details are currently available.

The full details in Polish can be found here, here, and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.